Tan Laren D, Nguyen Nolan, Alismail Abdullah, Castro Mario
Department of Internal Medicine, School of Medicine, Loma Linda University Health, Loma Linda, CA, USA.
Department of Cardiopulmonary Sciences, School of Allied Health Professions, Loma Linda, CA, USA.
J Asthma Allergy. 2022 Jun 29;15:875-883. doi: 10.2147/JAA.S369836. eCollection 2022.
Asthma continues to be a complex respiratory disease to control for many despite optimal standard inhaler therapy. The increased dependence on steroid-sparing biologic treatments in the 21 century has created a dilemma between identifying the patient's intrinsic biomarkers and their "life markers." With Tezepelumab being the most recent FDA-approved biologic for asthma, it is even more critical for asthma specialists to better understand and establish a framework to determine which biologic would work best for their patients. While cost and payor approvals limit access to certain asthma biologics, medical decisions on which biologic to select should be centered around shared decision-making, the rationale for biologic initiation, and critical biologic education to help achieve successful asthma control.
尽管采用了最佳的标准吸入器疗法，但对许多人来说，哮喘仍然是一种难以控制的复杂呼吸道疾病。21世纪对减少类固醇生物治疗的依赖性增加，这在识别患者的内在生物标志物和他们的“生命标志物”之间造成了两难境地。随着tezepelumab成为美国食品药品监督管理局（FDA）最近批准的用于治疗哮喘的生物制剂，哮喘专家更有必要更好地理解并建立一个框架，以确定哪种生物制剂对他们的患者效果最佳。虽然成本和医保支付方的批准限制了某些哮喘生物制剂的可及性，但关于选择哪种生物制剂的医疗决策应以共同决策、启动生物制剂的基本原理以及关键的生物制剂教育为中心，以帮助实现哮喘的成功控制。
